Abstract: The application discloses a pipeline annular self-traveling guide apparatus and a pipeline annular self-traveling guiding method. The pipeline annular self-traveling guide apparatus includes an inner annular groove and an outer annular groove. A first pipeline fixing part is configured on the inner annular groove, a second pipeline fixing part is configured on the outer annular groove, an annular bracket which is configured to rotate freely along a circumferential direction is correspondingly configured between the inner annular groove and the outer annular groove, a pipeline supporting roller group is configured on the annular bracket, and gaps for laying pipelines are reserved between a circumferential surface of the pipeline supporting roller and inner bottom surfaces of the inner annular groove and the outer annular groove.

Abstract: The application discloses a pipeline annular self-traveling guide apparatus and a pipeline annular self-traveling guiding method. The pipeline annular self-traveling guide apparatus includes an inner annular groove and an outer annular groove. A first pipeline fixing part is configured on the inner annular groove, a second pipeline fixing part is configured on the outer annular groove, an annular bracket which is configured to rotate freely along a circumferential direction is correspondingly configured between the inner annular groove and the outer annular groove, a pipeline supporting roller group is configured on the annular bracket, and gaps for laying pipelines are reserved between a circumferential surface of the pipeline supporting roller and inner bottom surfaces of the inner annular groove and the outer annular groove.

Abstract: The present invention provides a combination of an ERK1/2 inhibitor compound, 6,6-dimethyl-2-{2-[(1-methyl-1H-pyrazol-5-yl)amino]pyrimidin-4-yl}-5-[2-(morpholin-4-yl) ethyl]-5,6-dihydro-4H-thieno[2,3-c]pyrrol-4-one, or a pharmaceutically acceptable salt thereof with gemcitabine, or a pharmaceutically acceptable salt thereof preferably hydrochloride, or with gemcitabine, or a pharmaceutically acceptable salt thereof preferably hydrochloride, and nab-paclitaxel, and to methods of using the combination to treat certain disorders, such as pancreatic cancer, including pancreatic ductal adenocarcinoma (PDAC).

Abstract: The present invention relates to agonist antibodies that specifically bind to Notch 3 and activate signaling. The present invention includes antibodies binding to an epitope comprising the first Lin12 domain. The present invention also includes uses of these antibodies to treat or prevent Notch 3 related diseases or disorders.

Abstract: The present invention relates to agonist antibodies that specifically bind to Notch 3 and activate signaling. The present invention includes antibodies binding to an epitope comprising the first Lin12 domain. The present invention also includes uses of these antibodies to treat or prevent Notch 3 related diseases or disorders.

Abstract: The present invention relates to agonist antibodies that specifically bind to Notch 3 and activate signaling. The present invention includes antibodies binding to an epitope comprising the first Lin12 domain. The present invention also includes uses of these antibodies to treat or prevent Notch 3 related diseases or disorders.

Abstract: The present invention relates to agonist antibodies that specifically bind to Notch 3 and activate signaling. The present invention includes antibodies binding to an epitope comprising the first Lin12 domain. The present invention also includes uses of these antibodies to treat or prevent Notch 3 related diseases or disorders.

Abstract: The present invention relates to agonist antibodies that specifically bind to Notch 3 and activate signaling. The present invention includes antibodies binding to an epitope comprising the first Lin12 domain. The present invention also includes uses of these antibodies to treat or prevent Notch 3 related diseases or disorders.

Abstract: The present invention relates to agonist antibodies that specifically bind to Notch 3 and activate signaling. The present invention includes antibodies binding to an epitope comprising the first Lin12 domain. The present invention also includes uses of these antibodies to treat or prevent Notch 3 related diseases or disorders.

Abstract: The present invention relates to agonist antibodies that specifically bind to Notch 3 and activate signaling. The present invention includes antibodies binding to an epitope comprising the first Lin12 domain. The present invention also includes uses of these antibodies to treat or prevent Notch 3 related diseases or disorders.

Abstract: The present invention relates to agonist antibodies that specifically bind to Notch 3 and activate signaling. The present invention includes antibodies binding to an epitope comprising the first Lin12 domain. The present invention also includes uses of these antibodies to treat or prevent Notch 3 related diseases or disorders.